Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Common Equity (2019 - 2025)

Pulmonx (LUNG) has disclosed Common Equity for 7 consecutive years, with $60.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity changed N/A to $60.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $60.0 million, a N/A change, with the full-year FY2024 number at $85.8 million, down 27.47% from a year prior.
  • Common Equity was $60.0 million for Q3 2025 at Pulmonx, down from $69.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $216.1 million in Q1 2021 to a low of $60.0 million in Q3 2025.
  • A 5-year average of $135.1 million and a median of $134.0 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 211.39% in 2021, then tumbled 31.72% in 2025.
  • Pulmonx's Common Equity stood at $193.2 million in 2021, then fell by 20.3% to $154.0 million in 2022, then decreased by 23.18% to $118.3 million in 2023, then dropped by 27.47% to $85.8 million in 2024, then tumbled by 30.04% to $60.0 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Common Equity are $60.0 million (Q3 2025), $69.1 million (Q2 2025), and $77.7 million (Q1 2025).